Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
346 questions in 59 reviews · Vascular
current versionsNo studies 346 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Post‐thrombotic syndrome · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Berotralstat vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Disability (any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Disability(any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Avoralstat vs placebo Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Quality of lifestandardised mean difference(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Disability(any validated scale)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Lanadelumab vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Lanadelumab vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Avoralstat vs placebo Disability (any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Number of cannulation attempts · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Patient satisfaction NRS from 0 to 10 or 4‐step Likert scaleThe higher the score the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Overall success of cannulation · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Number of cannulation attempts · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Patient satisfaction NRS from 0 to 10 or 4‐step Likert scale The higher the score, the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Overall success of cannulation · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Heparin started before vs after the surgical procedure PE · people undergoing bariatric surgery Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Heparin started before vs after the surgical procedure Adverse events (thrombocytopenia) · people undergoing bariatric surgery Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined mechanical and pharmacological prophylaxis vs mechanical prophylaxis alone PE · people undergoing bariatric surgery Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined mechanical and pharmacological prophylaxis vs mechanical prophylaxis alone Adverse events · people undergoing bariatric surgery Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Valvuloplasty plus surgery of the superficial venous system vs surgery of the superficial venous system Ulcer healing and recurrence · people with non‐severe primary valvular incompetence Surgery for deep venous insufficiency (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs foam sclerotherapy QoL · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs foam sclerotherapy Persistence of symptoms · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs liquid sclerotherapy Complications ‐ DVT · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs liquid sclerotherapy QoL · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs liquid sclerotherapy Persistence of symptoms · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances Cosmetic appearance · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances Complications ‐ DVT · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances Residual varicose veins · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances QoL · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances Persistence of symptoms · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs sclerotherapy with different substances Recurrent varicose veins · participants with varicose veinsb Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam sclerotherapy vs placebo Recurrent varicose veins · participants with varicose veinsa Injection sclerotherapy for varicose veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole plus aspirin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole plus aspirin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Fish oil vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |